Heon Yoo

Prof. Heon Yoo

National Cancer Center Korea
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Journal of Korean Neurosurgical Society
Verified
Journal Article
Open access
PDF file
CLChang-Hyun Lee
Chang-Hyun Lee
KJKyu-Won Jung
Kyu-Won Jung
HYHeon Yoo
Heon Yoo
SPSohee Park
Sohee Park
SLSeung-Hoon Lee
Seung-Hoon Lee
The aim of this report is to provide accurate nationwide epidemiologic data on primary central nervous system (CNS) tumors in Korea. Despite its importance, there are no accurate statistics on primary CNS tumors in Korea. We analyzed primary CNS tumors diagnosed in 2005 from the nationwide registry. Data on primary CNS tumors diagnosed in 2005 were collected from the Korean Central Cancer Registry and the Korean Brain Tumor Society. Crude and age-standardized rates were calculated in terms of gender, age, and histological type. Tumors of uncertain histology were investigated individually at the corresponding hospitals and had their diagnoses confirmed. A total of 5,692 patients diagnosed with primary CNS tumors in 2005 were included in this study. CNS tumors occurred in females more often than in males (female to male, 1.43 : 1). The most common tumor was meningioma (31.2%). Glioblastoma accounted for 30.7% of all gliomas, and 19.3% of all malignant primary CNS tumors. In children under 19 years of age, both germ cell tumor and embryonal/primitive/medulloblastoma were the most common tumors. This article is the first nationwide primary CNS tumor epidemiology report in Korea. Data from this study should provide valuable information regarding the understanding of primary CNS tumors epidemiology in Korea.

1 January 2017 in Brain Tumor Research and Treatment
Verified
Journal Article
Open access
PDF file
YDYun-Sik Dho
Yun-Sik Dho
KJKyu-Won Jung
Kyu-Won Jung
JHJohyun Ha
Johyun Ha
YSYoungbeom Seo
Youngbeom Seo
CPChul-kee Park
Chul-kee Park
HYHeon Yoo
Heon Yoo
Dho YS, et al. Brain Tumor Res Treat. 2017 Apr;5(1):16-23. https://doi.org/10.14791/btrt.2017.5.1.16

27 March 2019 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
HKHye Seon Kim
Hye Seon Kim
JPJong Bae Park
Jong Bae Park
HGHo-Shin Gwak
Ho-Shin Gwak
JKJi-Woong Kwon
Ji-Woong Kwon
SSSang-Hoon Shin
Sang-Hoon Shin
HYHeon Yoo
Heon Yoo
Leptomeningeal carcinomatosis (LMC) is frequently associated with hydrocephalus, which quickly devastates the performance of the patient. Cerebrospinal fluid (CSF) shunt is a widely accepted treatment of choice, but the clinical outcomes in patients with LMC are not well studied. This study aimed to examine the efficacy of a CSF shunt in patients with LMC. Seventy patients with LMC confirmed by cytology or magnetic resonance imaging (MRI) underwent ventriculoperitoneal (VP) or lumboperitoneal (LP) shunt surgery. We retrospectively analyzed the clinical characteristics of patients, symptom improvement after the shunt, rate of complications associated with the surgery, and overall survival. Fifty-five patients had systemic cancer as a preceding disease, including lung cancer (45), breast cancer (6), and others (4). Primary brain tumors were mainly glioma (7) and medulloblastoma (5). Fifty-one patients had VP shunt, and 19 had LP shunt. After surgery, preoperative symptoms “improved” in 35 patients (50%) and were “normalized” in 24 of those patients (34%). Shunt malfunction occurred in eight patients, and infection occurred in eight patients. Seventeen patients underwent revision due to infection, shunt malfunction, or over-drainage. There were no complications associated with peritoneal seeding during a median follow-up of 3.3 months after surgery. The median overall survival was 8.7 months (95% confidence interval, 6.0–11.4) from LMC diagnosis and 4.1 months from shunt surgery. VP or LP shunt is effective for patients with hydrocephalus from LMC in terms of symptom improvement and prolonging of overall survival with an acceptable rate of procedure-related complications. This study was approved by the Institutional Review Board (IRB) of the National Cancer Center (retrospectively registered, NCC2018-0051 ).

1 July 2015 in Journal of Neurosurgery
Verified
Journal Article
Closed access
CPChang Hwan Pang
Chang Hwan Pang
SLSoo Eon Lee
Soo Eon Lee
CKChang Hyeun Kim
Chang Hyeun Kim
JKJeong Eun Kim
Jeong Eun Kim
HKHyun-Seung Kang
Hyun-Seung Kang
HYHeon Yoo
Heon Yoo
OBJECT: There is inconsistency among the perioperative management strategies currently used for chronic subdural hematoma (cSDH). Moreover, postoperative complications such as acute intracranial bleeding and cSDH recurrence affect clinical outcome of cSDH surgery. This study evaluated the risk factors associated with acute intracranial bleeding and cSDH recurrence and identified an effective perioperative strategy for cSDH patients. METHODS: A retrospective study of patients who underwent bur hole craniostomy for cSDH between 2008 and 2012 was performed. RESULTS: A consecutive series of 303 cSDH patients (234 males and 69 females; mean age 67.17 years) was analyzed. Postoperative acute intracranial bleeding developed in 14 patients (4.57%) within a mean of 3.07 days and recurrence was observed in 37 patients (12.21%) within a mean of 31.69 days (range 10–104 days) after initial bur hole craniostomy. The comorbidities of hematological disease and prior shunt surgery were clinical factors associated with acute bleeding. There was a significant risk of recurrence in patients with diabetes mellitus, but recurrence did not affect the final neurological outcome (p = 0.776). Surgical details, including the number of operative bur holes, saline irrigation of the hematoma cavity, use of a drain, and type of postoperative ambulation, were not significantly associated with outcome. However, a large amount of drainage was associated with postoperative acute bleeding. CONCLUSIONS: Bur hole craniostomy is an effective surgical procedure for initial and recurrent cSDH. Patients with hematological disease or a history of prior shunt surgery are at risk for postoperative acute bleeding; therefore, these patients should be carefully monitored to avoid overdrainage. Surgeons should consider informing patients with diabetes mellitus that this comorbidity is associated with an increased likelihood of recurrence.

1 November 2002
Verified
Journal Article
Closed access
MPMyung-Jin Park
Myung-Jin Park
MKMi-Suk Kim
Mi-Suk Kim
IPIn-Chul Park
In-Chul Park
HKHee-Seok Kang
Hee-Seok Kang
HYHeon Yoo
Heon Yoo
DLDong-Seok Lee
Dong-Seok Lee

15 April 2017 in Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
SLSeung Hoon Lee
Seung Hoon Lee
KJKyu-Won Jung
Kyu-Won Jung
JHJohyun Ha
Johyun Ha
COChang-Mo Oh
Chang-Mo Oh
HKHyeseon Kim
Hyeseon Kim
YWYoung-Joo Won
Young-Joo Won
Malignant central nervous system (CNS) germ cell tumors (GCTs), although rare, are thought to occur more frequently among Asians. However, a recent population-based study revealed no differences in GCT incidence between Asians and Caucasians. Therefore, this study was conducted to determine the incidence and survival rates of CNS GCTs using the national cancer incidence database, and to compare these rates to those in the United States and Japan. We extracted CNS GCT patients diagnosed between 2005 and 2012 from the Korea Central Cancer Registry database. Age-standardized rates (ASRs), annual percentage change, and the male-female incidence rate ratios (IRRs) were calculated. To estimate the survival rate, we used data for patients diagnosed between 2005 and 2010 and followed their cases until December 31, 2013. The ASR for CNS GCT between 2005 and 2012 was 0.179 per 100,000 (95% confidence interval, 0.166 to 0.193), with an overall male-to-female (M:F) IRR of 2.95:1. However, when stratified by site, the M:F IRR was 13.62:1 for tumors of the pineal region and 1.87:1 for those located in nonpineal regions. The most frequent histologic type was germinoma (76.0%), and the most frequent location was the suprasellar region (48.5%). The 5-year survival rate of germinoma patients was 95.3%. The incidence rate of CNS GCTs in Korea during 2005-2012 was 0.179 per 100,000, which was similar to that of the Asian/Pacific Islander subpopulation in the United States. Moreover, the CNS GCT survival rate in Korea was similar to rates in Japan and the United States.